Combining irbesartan and trichlormethiazide enhances blood pressure reduction via inhibition of sympathetic activity without adverse effects on metabolism in hypertensive rats with metabolic syndrome

Masaaki Nishihara, Yoshitaka Hirooka, Kenji Sunagawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Sympathoexcitation and oxidative stress in the brain have pivotal roles in hypertension with metabolic syndrome (MetS). Here, we examined whether oral administration of irbesartan (IRB) and trichlormethiazide (TCM) decreases blood pressure (BP) via inhibiting sympathetic activity through anti-oxidant effects in the brain of spontaneously hypertensive rats (SHR-cp). IRB/TCM treatment decreased BP more profoundly than IRB monotherapy. Urinary norepinephrine excretion and oxidative stress in the brain were decreased in both IRB and IRB/TCM groups without any adverse effect on the metabolic profile. These findings suggest that IRB/TCM profoundly decreases BP in SHR-cp by inhibiting sympathetic activity via anti-oxidant effects in the brain.

Original languageEnglish
Pages (from-to)33-38
Number of pages6
JournalClinical and Experimental Hypertension
Volume37
Issue number1
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

irbesartan
Trichlormethiazide
Blood Pressure
Brain
Oxidative Stress
Antioxidants
Metabolome
Inbred SHR Rats
Oral Administration
Norepinephrine

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology

Cite this

@article{f5b1b2b5686a4b5895c040b1aabdd4cd,
title = "Combining irbesartan and trichlormethiazide enhances blood pressure reduction via inhibition of sympathetic activity without adverse effects on metabolism in hypertensive rats with metabolic syndrome",
abstract = "Sympathoexcitation and oxidative stress in the brain have pivotal roles in hypertension with metabolic syndrome (MetS). Here, we examined whether oral administration of irbesartan (IRB) and trichlormethiazide (TCM) decreases blood pressure (BP) via inhibiting sympathetic activity through anti-oxidant effects in the brain of spontaneously hypertensive rats (SHR-cp). IRB/TCM treatment decreased BP more profoundly than IRB monotherapy. Urinary norepinephrine excretion and oxidative stress in the brain were decreased in both IRB and IRB/TCM groups without any adverse effect on the metabolic profile. These findings suggest that IRB/TCM profoundly decreases BP in SHR-cp by inhibiting sympathetic activity via anti-oxidant effects in the brain.",
author = "Masaaki Nishihara and Yoshitaka Hirooka and Kenji Sunagawa",
year = "2015",
month = "2",
day = "1",
doi = "10.3109/10641963.2014.897719",
language = "English",
volume = "37",
pages = "33--38",
journal = "Clinical and Experimental Hypertension",
issn = "1064-1963",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Combining irbesartan and trichlormethiazide enhances blood pressure reduction via inhibition of sympathetic activity without adverse effects on metabolism in hypertensive rats with metabolic syndrome

AU - Nishihara, Masaaki

AU - Hirooka, Yoshitaka

AU - Sunagawa, Kenji

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Sympathoexcitation and oxidative stress in the brain have pivotal roles in hypertension with metabolic syndrome (MetS). Here, we examined whether oral administration of irbesartan (IRB) and trichlormethiazide (TCM) decreases blood pressure (BP) via inhibiting sympathetic activity through anti-oxidant effects in the brain of spontaneously hypertensive rats (SHR-cp). IRB/TCM treatment decreased BP more profoundly than IRB monotherapy. Urinary norepinephrine excretion and oxidative stress in the brain were decreased in both IRB and IRB/TCM groups without any adverse effect on the metabolic profile. These findings suggest that IRB/TCM profoundly decreases BP in SHR-cp by inhibiting sympathetic activity via anti-oxidant effects in the brain.

AB - Sympathoexcitation and oxidative stress in the brain have pivotal roles in hypertension with metabolic syndrome (MetS). Here, we examined whether oral administration of irbesartan (IRB) and trichlormethiazide (TCM) decreases blood pressure (BP) via inhibiting sympathetic activity through anti-oxidant effects in the brain of spontaneously hypertensive rats (SHR-cp). IRB/TCM treatment decreased BP more profoundly than IRB monotherapy. Urinary norepinephrine excretion and oxidative stress in the brain were decreased in both IRB and IRB/TCM groups without any adverse effect on the metabolic profile. These findings suggest that IRB/TCM profoundly decreases BP in SHR-cp by inhibiting sympathetic activity via anti-oxidant effects in the brain.

UR - http://www.scopus.com/inward/record.url?scp=84921304713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921304713&partnerID=8YFLogxK

U2 - 10.3109/10641963.2014.897719

DO - 10.3109/10641963.2014.897719

M3 - Article

C2 - 24678944

AN - SCOPUS:84921304713

VL - 37

SP - 33

EP - 38

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

SN - 1064-1963

IS - 1

ER -